InProTher is developing adaptive immune therapies that target human endogenous retroviruses (HERVs), a class of dark genome antigens associated with cancer and aging-related diseases. This approach aims to enhance the immune system's ability to combat these diseases, potentially improving patient outcomes in oncology and age-related health conditions.
Funding
$11.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers and aging-related diseases are associated with human endogenous retroviruses (HERVs), a class of antigens derived from the "dark genome." The immune system often fails to recognize and target these HERV antigens, hindering effective treatment of these diseases.
Solution
HERVolution Therapeutics is developing adaptive immunotherapies specifically engineered to target HERVs. By directing the immune system to recognize and attack cells expressing these dark genome antigens, the company aims to enhance the body's natural defenses against cancer and aging-related diseases. This approach has the potential to improve patient outcomes by providing a more targeted and effective treatment strategy.
Target Audience
The primary target audience includes patients with cancers and aging-related diseases where HERV expression plays a significant role, as well as oncology and geriatric healthcare providers.
Features
- Adaptive immunotherapies targeting HERV antigens
- Focus on cancers and aging-related diseases linked to HERV expression
- Engineered to enhance immune system recognition of dark genome antigens